Therapix Biosciences (NASDAQ:TRPX) received an initiation of coverage from Laidlaw & Company analyst Francois Brisebois who gave the company a Buy rating and a $18.00 price target. Therapix’s lead drug is an FDA approved dronabinol, which is a biosynthetic form of THC. The company’s strategy is to repurpose, reposition and improve the FDA approved cannabinoid for various....More>>>
Gold (SPDR Gold Shares GLD) added 1.95% since the start of this year. Gold miners (VanEck Vectors Gold Miners GDX) soared more than 7% – outperforming almost every single ETF this year.
In this article, I want to explain how this could happen and what I think is going to happen next.
As most of you know, I wrote a few bearish articles during the past few months. Below are two....More>>>
Pfizer (NYSE:PFE) has been gaining a lot of momentum recently with its share price having risen almost 7% since the 24th of January. The stock has been riding the biotech wave since the complex bottomed back in November but also has traded strongly since it announced its fourth quarter results at the end of January. Although the company missed earnings expectation in Q4 due to established....More>>>
A few things will need to happen for oil to reach and hold $60 a barrel, as it has started its march in that direction and recently jumped above $54. The new OPEC deal, largely supported by many other producing nations, will need to hold. U.S. shale production cannot pick up too quickly. The signs of a global economic rebound cannot be interrupted.
On top of all that, the IEA Oil Market Report....More>>>
Related TWTR Does Pok茅mon GO Pose National Security Risk? Putting Pok茅mon GO's Massive Popularity Into Perspective Is Twitter The Future Of News Broadcast? (Seeking Alpha) Related Credit Suisse Bullish On Antero Resources, Raises Price Target Baird Sees Antero Midstream As An 'Undervalued....More>>>